Mobile Cardiac Telemetry is essential to mitigate cardiac issues that patients may experience during COVID-19 treatment protocols. Topelia Therapeutics and InfoBionic have partnered in a remote cardiac monitoring 24-week clinical study
(Waltham, MA), September 8, 2020—Ventura, CA-based Topelia Therapeutics selected InfoBionic as its partner in EKG pre-screening and continuous remote cardiac monitoring services for patients enrolled in their NIH–approved clinical trial Quintuple therapy to treat COVID-19 Infection (HAZDpaC).
This Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) for the treatment of patients who test positive for the COVID-19 virus. This is a randomized, double-blind, placebo-controlled study. Individuals included in the clinical trial are treated with this quintuple therapy for 10-days. The study will last 24–weeks with up to 600 participants. Topelia Therapeutics is actively recruiting patients for this study. Visit https:/topeliatherapeutics.com/clinical-trials.
Dr. Sabine Hazan, the clinical trial Principal Investigator stated, “Patient safety is paramount in all our protocols. Our team understands the importance of the initial EKG screening and continuous remote cardiac monitoring for patients on the prescribed therapy.” Further, “Partnering with InfoBionic was made easier when in response to the COVID-19 pandemic, InfoBionic released a new set of features designed specifically to help in monitoring and diagnosing QT prolongation.”
Dr. Hazan has spent more than 2 decades working with the FDA and NIH to bring medicine to new frontiers, she believes there will always be a place for pharmaceutical clinical trials, and hopes to demonstrate that effective, low-cost solutions are available to treat some of today’s most challenging medical conditions.
Cardiology medical expert Dr. Alon Steinberg, the designated Safety and Medical Monitoring physician supporting the trial, was already familiar with the solution and stated, “InfoBionic meets our needs; the device is easy for the patients to use and the advanced full disclosure monitoring and reporting functions ensure patient safety, making this trial and partnership a success.”
Dave MacCutcheon, InfoBionic COO, remarked, “We are excited to be working with the Topelia Therapeutics team on COVID-19 solutions. This trial complements our ReMoteMeTM program that delivers EKG devices directly to patients’ homes, as many are still unable to visit their doctors’ offices due to current quarantine restrictions.”
Topelia Therapeutics and InfoBionic are committed to providing comprehensive, safe, and innovative solutions that further improve the lives of all people during this unprecedented time.
About Topelia Therapeutics
Strategically placed as a genetic sequencing lab, site, CRO, and now sponsor, Topelia Therapeutics has six COVID-19 studies validating testing, prophylaxis, and treatment protocols for the novel coronavirus. For more, visit: https://TopeliaTheraputics .com
InfoBionic is a digital health company transforming the efficiency and economics of ambulatory remote patient monitoring processes by optimizing clinical and real-world utility for the users that need it most – physicians and their patients. The Massachusetts-based team of seasoned entrepreneurs have had successful careers in healthcare, IT, medical devices, and mobile technology, and bring specific expertise in remote monitoring and cardiology. They have seen first-hand the complexities of traditional cardiac arrhythmia detection and monitoring processes and designed the transformative MoMe® Kardia platform to remove the roadblocks hindering faster, more effective diagnosis and decision-making. Frost & Sullivan bestowed the 2019 North American Remote Cardiac Monitoring Technology Leadership Award upon InfoBionic. For more, visit: https://infobionic.com.
Karla Jo Helms